**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

05882.0168.CPUS01

APPLICATION NO.

09/930,020

APPLICANTS

Kurt C. Gish, et al.

FILING DATE

August 14, 2001

GROUP

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SR	1.	WO 00/55633 A	09-21-2000	PCT				
↓	2.	Supplementary Partial European Search Report	11-15-2004	EPO				

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)


SR	3.	Karnes, et al., "Inhibition Of Epidermal Growth Factor Receptor Kinase Induces Protease-Dependent Apoptosis in Human Colon Cancer Cells," <i>Gastroenterol.</i> , 114: 930-9 (1998)						

12 5/26/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/930,020
		Filing Date	August 14, 2001
		First Named Inventor	Kurt C. Gish
		Group Art Unit	1642
		Examiner Name	Stephen L. Rawlings
		Attorney Docket Number	05882.0168.CPUS01
1	of	1	



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
SK ↓	C1	Fetrow, J.S., et al., "Method For Prediction Of Protein Function From Sequence Using The Sequence-To-Structure-To-Function Paradigm With Application To Glutaredoxins/Thioredoxins And T1 Ribonucleases," Journal Mol. Biol., Vol. 281, No. 5, pp. 949-968 (September 4, 1998)(Abstract)	
	C2	Rost, Burkhard, "Twilight Zone of Protein Sequence Alignments," Protein Engineering, Vol. 12, No. 2, pp. 85-94 (1999)	

Examiner Signature		Date Considered	5/26/08
---------------------------	--	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.